nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CYP3A4—Cytarabine—lymphatic system cancer	0.0246	0.318	CbGbCtD
Cevimeline—CYP3A4—Teniposide—lymphatic system cancer	0.0242	0.313	CbGbCtD
Cevimeline—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0169	0.219	CbGbCtD
Cevimeline—CYP3A4—Vincristine—lymphatic system cancer	0.0116	0.151	CbGbCtD
Cevimeline—Alopecia—Carmustine—lymphatic system cancer	0.00107	0.00115	CcSEcCtD
Cevimeline—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00106	0.00115	CcSEcCtD
Cevimeline—Body temperature increased—Fludarabine—lymphatic system cancer	0.00106	0.00115	CcSEcCtD
Cevimeline—Vaginal infection—Methotrexate—lymphatic system cancer	0.00105	0.00114	CcSEcCtD
Cevimeline—Malnutrition—Carmustine—lymphatic system cancer	0.00105	0.00114	CcSEcCtD
Cevimeline—Cough—Bleomycin—lymphatic system cancer	0.00105	0.00114	CcSEcCtD
Cevimeline—Angiopathy—Vincristine—lymphatic system cancer	0.00104	0.00113	CcSEcCtD
Cevimeline—Diarrhoea—Teniposide—lymphatic system cancer	0.00104	0.00113	CcSEcCtD
Cevimeline—Myalgia—Bleomycin—lymphatic system cancer	0.00102	0.00111	CcSEcCtD
Cevimeline—Chest pain—Bleomycin—lymphatic system cancer	0.00102	0.00111	CcSEcCtD
Cevimeline—Alopecia—Vincristine—lymphatic system cancer	0.00102	0.0011	CcSEcCtD
Cevimeline—Coma—Methotrexate—lymphatic system cancer	0.00102	0.0011	CcSEcCtD
Cevimeline—Back pain—Carmustine—lymphatic system cancer	0.00101	0.0011	CcSEcCtD
Cevimeline—Discomfort—Bleomycin—lymphatic system cancer	0.00101	0.0011	CcSEcCtD
Cevimeline—Chills—Mitoxantrone—lymphatic system cancer	0.00101	0.00109	CcSEcCtD
Cevimeline—Neoplasm—Methotrexate—lymphatic system cancer	0.00101	0.00109	CcSEcCtD
Cevimeline—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00101	0.00109	CcSEcCtD
Cevimeline—Urine output increased—Methotrexate—lymphatic system cancer	0.00101	0.00109	CcSEcCtD
Cevimeline—Bladder pain—Methotrexate—lymphatic system cancer	0.00101	0.00109	CcSEcCtD
Cevimeline—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.001	0.00108	CcSEcCtD
Cevimeline—Alopecia—Mitoxantrone—lymphatic system cancer	0.00099	0.00107	CcSEcCtD
Cevimeline—Confusional state—Bleomycin—lymphatic system cancer	0.000989	0.00107	CcSEcCtD
Cevimeline—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000986	0.00107	CcSEcCtD
Cevimeline—Tremor—Carmustine—lymphatic system cancer	0.000983	0.00107	CcSEcCtD
Cevimeline—Oedema—Bleomycin—lymphatic system cancer	0.000981	0.00106	CcSEcCtD
Cevimeline—Infection—Bleomycin—lymphatic system cancer	0.000975	0.00106	CcSEcCtD
Cevimeline—Anaemia—Carmustine—lymphatic system cancer	0.00097	0.00105	CcSEcCtD
Cevimeline—Back pain—Vincristine—lymphatic system cancer	0.000969	0.00105	CcSEcCtD
Cevimeline—Vomiting—Teniposide—lymphatic system cancer	0.000968	0.00105	CcSEcCtD
Cevimeline—Sepsis—Methotrexate—lymphatic system cancer	0.000965	0.00105	CcSEcCtD
Cevimeline—Agitation—Carmustine—lymphatic system cancer	0.000964	0.00105	CcSEcCtD
Cevimeline—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000961	0.00104	CcSEcCtD
Cevimeline—Asthenia—Fludarabine—lymphatic system cancer	0.00096	0.00104	CcSEcCtD
Cevimeline—Rash—Teniposide—lymphatic system cancer	0.00096	0.00104	CcSEcCtD
Cevimeline—Dermatitis—Teniposide—lymphatic system cancer	0.000959	0.00104	CcSEcCtD
Cevimeline—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000955	0.00104	CcSEcCtD
Cevimeline—Headache—Teniposide—lymphatic system cancer	0.000954	0.00103	CcSEcCtD
Cevimeline—Pruritus—Fludarabine—lymphatic system cancer	0.000947	0.00103	CcSEcCtD
Cevimeline—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000946	0.00103	CcSEcCtD
Cevimeline—Back pain—Mitoxantrone—lymphatic system cancer	0.000944	0.00102	CcSEcCtD
Cevimeline—Leukopenia—Carmustine—lymphatic system cancer	0.000939	0.00102	CcSEcCtD
Cevimeline—Anorexia—Bleomycin—lymphatic system cancer	0.000935	0.00101	CcSEcCtD
Cevimeline—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000932	0.00101	CcSEcCtD
Cevimeline—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000928	0.00101	CcSEcCtD
Cevimeline—Anaemia—Vincristine—lymphatic system cancer	0.000926	0.001	CcSEcCtD
Cevimeline—Agitation—Vincristine—lymphatic system cancer	0.000921	0.000998	CcSEcCtD
Cevimeline—Polyuria—Methotrexate—lymphatic system cancer	0.000919	0.000996	CcSEcCtD
Cevimeline—Hypotension—Bleomycin—lymphatic system cancer	0.000917	0.000994	CcSEcCtD
Cevimeline—Diarrhoea—Fludarabine—lymphatic system cancer	0.000916	0.000992	CcSEcCtD
Cevimeline—Convulsion—Carmustine—lymphatic system cancer	0.000909	0.000985	CcSEcCtD
Cevimeline—Hypertension—Carmustine—lymphatic system cancer	0.000906	0.000982	CcSEcCtD
Cevimeline—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000905	0.000981	CcSEcCtD
Cevimeline—Nausea—Teniposide—lymphatic system cancer	0.000904	0.00098	CcSEcCtD
Cevimeline—Anaemia—Mitoxantrone—lymphatic system cancer	0.000902	0.000977	CcSEcCtD
Cevimeline—Vertigo—Vincristine—lymphatic system cancer	0.0009	0.000975	CcSEcCtD
Cevimeline—Leukopenia—Vincristine—lymphatic system cancer	0.000897	0.000972	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000894	0.000969	CcSEcCtD
Cevimeline—Myalgia—Carmustine—lymphatic system cancer	0.000893	0.000968	CcSEcCtD
Cevimeline—Chest pain—Carmustine—lymphatic system cancer	0.000893	0.000968	CcSEcCtD
Cevimeline—Anxiety—Carmustine—lymphatic system cancer	0.00089	0.000965	CcSEcCtD
Cevimeline—Paraesthesia—Bleomycin—lymphatic system cancer	0.000881	0.000955	CcSEcCtD
Cevimeline—Malaise—Mitoxantrone—lymphatic system cancer	0.00088	0.000953	CcSEcCtD
Cevimeline—Dyspnoea—Bleomycin—lymphatic system cancer	0.000875	0.000948	CcSEcCtD
Cevimeline—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000873	0.000946	CcSEcCtD
Cevimeline—Convulsion—Vincristine—lymphatic system cancer	0.000868	0.000941	CcSEcCtD
Cevimeline—Hypertension—Vincristine—lymphatic system cancer	0.000865	0.000937	CcSEcCtD
Cevimeline—Confusional state—Carmustine—lymphatic system cancer	0.000864	0.000936	CcSEcCtD
Cevimeline—Oedema—Carmustine—lymphatic system cancer	0.000856	0.000928	CcSEcCtD
Cevimeline—Decreased appetite—Bleomycin—lymphatic system cancer	0.000853	0.000924	CcSEcCtD
Cevimeline—Myalgia—Vincristine—lymphatic system cancer	0.000853	0.000924	CcSEcCtD
Cevimeline—Cough—Mitoxantrone—lymphatic system cancer	0.000851	0.000923	CcSEcCtD
Cevimeline—Infection—Carmustine—lymphatic system cancer	0.000851	0.000922	CcSEcCtD
Cevimeline—Vomiting—Fludarabine—lymphatic system cancer	0.000851	0.000922	CcSEcCtD
Cevimeline—Convulsion—Mitoxantrone—lymphatic system cancer	0.000845	0.000916	CcSEcCtD
Cevimeline—Rash—Fludarabine—lymphatic system cancer	0.000844	0.000914	CcSEcCtD
Cevimeline—Dermatitis—Fludarabine—lymphatic system cancer	0.000843	0.000914	CcSEcCtD
Cevimeline—Hypertension—Mitoxantrone—lymphatic system cancer	0.000842	0.000913	CcSEcCtD
Cevimeline—Pain—Bleomycin—lymphatic system cancer	0.000839	0.000909	CcSEcCtD
Cevimeline—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000838	0.000909	CcSEcCtD
Cevimeline—Headache—Fludarabine—lymphatic system cancer	0.000838	0.000909	CcSEcCtD
Cevimeline—Tachycardia—Carmustine—lymphatic system cancer	0.000836	0.000906	CcSEcCtD
Cevimeline—Chest pain—Mitoxantrone—lymphatic system cancer	0.000831	0.0009	CcSEcCtD
Cevimeline—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000831	0.0009	CcSEcCtD
Cevimeline—Myalgia—Mitoxantrone—lymphatic system cancer	0.000831	0.0009	CcSEcCtD
Cevimeline—Anxiety—Mitoxantrone—lymphatic system cancer	0.000828	0.000897	CcSEcCtD
Cevimeline—Discomfort—Mitoxantrone—lymphatic system cancer	0.000821	0.000889	CcSEcCtD
Cevimeline—Oedema—Vincristine—lymphatic system cancer	0.000818	0.000886	CcSEcCtD
Cevimeline—Anorexia—Carmustine—lymphatic system cancer	0.000816	0.000885	CcSEcCtD
Cevimeline—Infection—Vincristine—lymphatic system cancer	0.000812	0.00088	CcSEcCtD
Cevimeline—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000808	0.000876	CcSEcCtD
Cevimeline—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000807	0.000875	CcSEcCtD
Cevimeline—Confusional state—Mitoxantrone—lymphatic system cancer	0.000803	0.00087	CcSEcCtD
Cevimeline—Nervous system disorder—Vincristine—lymphatic system cancer	0.000802	0.000869	CcSEcCtD
Cevimeline—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0008	0.000868	CcSEcCtD
Cevimeline—Hypotension—Carmustine—lymphatic system cancer	0.0008	0.000867	CcSEcCtD
Cevimeline—Oedema—Mitoxantrone—lymphatic system cancer	0.000796	0.000863	CcSEcCtD
Cevimeline—Nausea—Fludarabine—lymphatic system cancer	0.000795	0.000861	CcSEcCtD
Cevimeline—Infection—Mitoxantrone—lymphatic system cancer	0.000791	0.000857	CcSEcCtD
Cevimeline—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00079	0.000857	CcSEcCtD
Cevimeline—Shock—Mitoxantrone—lymphatic system cancer	0.000783	0.000849	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00078	0.000846	CcSEcCtD
Cevimeline—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00078	0.000845	CcSEcCtD
Cevimeline—Urticaria—Bleomycin—lymphatic system cancer	0.000779	0.000845	CcSEcCtD
Cevimeline—Anorexia—Vincristine—lymphatic system cancer	0.000779	0.000845	CcSEcCtD
Cevimeline—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000777	0.000842	CcSEcCtD
Cevimeline—Body temperature increased—Bleomycin—lymphatic system cancer	0.000776	0.000841	CcSEcCtD
Cevimeline—Insomnia—Carmustine—lymphatic system cancer	0.000775	0.000839	CcSEcCtD
Cevimeline—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000773	0.000838	CcSEcCtD
Cevimeline—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00077	0.000834	CcSEcCtD
Cevimeline—Paraesthesia—Carmustine—lymphatic system cancer	0.000769	0.000833	CcSEcCtD
Cevimeline—Mood swings—Methotrexate—lymphatic system cancer	0.000765	0.000829	CcSEcCtD
Cevimeline—Hypotension—Vincristine—lymphatic system cancer	0.000764	0.000828	CcSEcCtD
Cevimeline—Dyspnoea—Carmustine—lymphatic system cancer	0.000763	0.000827	CcSEcCtD
Cevimeline—Somnolence—Carmustine—lymphatic system cancer	0.000761	0.000825	CcSEcCtD
Cevimeline—Anorexia—Mitoxantrone—lymphatic system cancer	0.000759	0.000823	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000745	0.000807	CcSEcCtD
Cevimeline—Decreased appetite—Carmustine—lymphatic system cancer	0.000744	0.000807	CcSEcCtD
Cevimeline—Hypotension—Mitoxantrone—lymphatic system cancer	0.000744	0.000806	CcSEcCtD
Cevimeline—Insomnia—Vincristine—lymphatic system cancer	0.000739	0.000801	CcSEcCtD
Cevimeline—Paraesthesia—Vincristine—lymphatic system cancer	0.000734	0.000796	CcSEcCtD
Cevimeline—Constipation—Carmustine—lymphatic system cancer	0.000732	0.000794	CcSEcCtD
Cevimeline—Pain—Carmustine—lymphatic system cancer	0.000732	0.000794	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000725	0.000786	CcSEcCtD
Cevimeline—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000723	0.000783	CcSEcCtD
Cevimeline—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000715	0.000775	CcSEcCtD
Cevimeline—Decreased appetite—Vincristine—lymphatic system cancer	0.000711	0.00077	CcSEcCtD
Cevimeline—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00071	0.000769	CcSEcCtD
Cevimeline—Somnolence—Mitoxantrone—lymphatic system cancer	0.000708	0.000767	CcSEcCtD
Cevimeline—Feeling abnormal—Carmustine—lymphatic system cancer	0.000706	0.000765	CcSEcCtD
Cevimeline—Fatigue—Vincristine—lymphatic system cancer	0.000705	0.000764	CcSEcCtD
Cevimeline—Asthenia—Bleomycin—lymphatic system cancer	0.000704	0.000763	CcSEcCtD
Cevimeline—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000701	0.00076	CcSEcCtD
Cevimeline—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.0007	0.000759	CcSEcCtD
Cevimeline—Pain—Vincristine—lymphatic system cancer	0.000699	0.000758	CcSEcCtD
Cevimeline—Constipation—Vincristine—lymphatic system cancer	0.000699	0.000758	CcSEcCtD
Cevimeline—Asthma—Methotrexate—lymphatic system cancer	0.000698	0.000756	CcSEcCtD
Cevimeline—Pruritus—Bleomycin—lymphatic system cancer	0.000694	0.000752	CcSEcCtD
Cevimeline—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000692	0.00075	CcSEcCtD
Cevimeline—Eosinophilia—Methotrexate—lymphatic system cancer	0.000691	0.000749	CcSEcCtD
Cevimeline—Fatigue—Mitoxantrone—lymphatic system cancer	0.000686	0.000744	CcSEcCtD
Cevimeline—Pain—Mitoxantrone—lymphatic system cancer	0.000681	0.000738	CcSEcCtD
Cevimeline—Constipation—Mitoxantrone—lymphatic system cancer	0.000681	0.000738	CcSEcCtD
Cevimeline—Abdominal pain—Carmustine—lymphatic system cancer	0.000677	0.000734	CcSEcCtD
Cevimeline—Body temperature increased—Carmustine—lymphatic system cancer	0.000677	0.000734	CcSEcCtD
Cevimeline—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000668	0.000725	CcSEcCtD
Cevimeline—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000656	0.000711	CcSEcCtD
Cevimeline—Dysuria—Methotrexate—lymphatic system cancer	0.000652	0.000707	CcSEcCtD
Cevimeline—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000651	0.000706	CcSEcCtD
Cevimeline—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000648	0.000703	CcSEcCtD
Cevimeline—Body temperature increased—Vincristine—lymphatic system cancer	0.000646	0.0007	CcSEcCtD
Cevimeline—Abdominal pain—Vincristine—lymphatic system cancer	0.000646	0.0007	CcSEcCtD
Cevimeline—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000642	0.000696	CcSEcCtD
Cevimeline—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000637	0.00069	CcSEcCtD
Cevimeline—Urticaria—Mitoxantrone—lymphatic system cancer	0.000632	0.000685	CcSEcCtD
Cevimeline—Hypersensitivity—Carmustine—lymphatic system cancer	0.000631	0.000684	CcSEcCtD
Cevimeline—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000629	0.000682	CcSEcCtD
Cevimeline—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000629	0.000682	CcSEcCtD
Cevimeline—Pneumonia—Methotrexate—lymphatic system cancer	0.000626	0.000678	CcSEcCtD
Cevimeline—Vomiting—Bleomycin—lymphatic system cancer	0.000624	0.000676	CcSEcCtD
Cevimeline—Depression—Methotrexate—lymphatic system cancer	0.00062	0.000672	CcSEcCtD
Cevimeline—Rash—Bleomycin—lymphatic system cancer	0.000619	0.00067	CcSEcCtD
Cevimeline—Dermatitis—Bleomycin—lymphatic system cancer	0.000618	0.00067	CcSEcCtD
Cevimeline—Asthenia—Carmustine—lymphatic system cancer	0.000614	0.000666	CcSEcCtD
Cevimeline—Stomatitis—Methotrexate—lymphatic system cancer	0.000606	0.000657	CcSEcCtD
Cevimeline—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000605	0.000655	CcSEcCtD
Cevimeline—Hypersensitivity—Vincristine—lymphatic system cancer	0.000602	0.000653	CcSEcCtD
Cevimeline—Haematuria—Methotrexate—lymphatic system cancer	0.000593	0.000643	CcSEcCtD
Cevimeline—Epistaxis—Methotrexate—lymphatic system cancer	0.000587	0.000636	CcSEcCtD
Cevimeline—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000587	0.000636	CcSEcCtD
Cevimeline—Asthenia—Vincristine—lymphatic system cancer	0.000587	0.000636	CcSEcCtD
Cevimeline—Diarrhoea—Carmustine—lymphatic system cancer	0.000586	0.000635	CcSEcCtD
Cevimeline—Nausea—Bleomycin—lymphatic system cancer	0.000583	0.000632	CcSEcCtD
Cevimeline—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00058	0.000629	CcSEcCtD
Cevimeline—Asthenia—Mitoxantrone—lymphatic system cancer	0.000571	0.000619	CcSEcCtD
Cevimeline—Dizziness—Carmustine—lymphatic system cancer	0.000566	0.000614	CcSEcCtD
Cevimeline—Haemoglobin—Methotrexate—lymphatic system cancer	0.000561	0.000608	CcSEcCtD
Cevimeline—Diarrhoea—Vincristine—lymphatic system cancer	0.000559	0.000606	CcSEcCtD
Cevimeline—Haemorrhage—Methotrexate—lymphatic system cancer	0.000558	0.000605	CcSEcCtD
Cevimeline—Pharyngitis—Methotrexate—lymphatic system cancer	0.000554	0.000601	CcSEcCtD
Cevimeline—Urethral disorder—Methotrexate—lymphatic system cancer	0.000547	0.000593	CcSEcCtD
Cevimeline—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000545	0.00059	CcSEcCtD
Cevimeline—Vomiting—Carmustine—lymphatic system cancer	0.000545	0.00059	CcSEcCtD
Cevimeline—Dizziness—Vincristine—lymphatic system cancer	0.000541	0.000586	CcSEcCtD
Cevimeline—Rash—Carmustine—lymphatic system cancer	0.00054	0.000585	CcSEcCtD
Cevimeline—Dermatitis—Carmustine—lymphatic system cancer	0.000539	0.000585	CcSEcCtD
Cevimeline—Visual impairment—Methotrexate—lymphatic system cancer	0.000538	0.000583	CcSEcCtD
Cevimeline—Headache—Carmustine—lymphatic system cancer	0.000536	0.000581	CcSEcCtD
Cevimeline—Eye disorder—Methotrexate—lymphatic system cancer	0.000522	0.000566	CcSEcCtD
Cevimeline—Tinnitus—Methotrexate—lymphatic system cancer	0.000521	0.000564	CcSEcCtD
Cevimeline—Vomiting—Vincristine—lymphatic system cancer	0.00052	0.000563	CcSEcCtD
Cevimeline—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000518	0.000562	CcSEcCtD
Cevimeline—Rash—Vincristine—lymphatic system cancer	0.000515	0.000559	CcSEcCtD
Cevimeline—Dermatitis—Vincristine—lymphatic system cancer	0.000515	0.000558	CcSEcCtD
Cevimeline—Headache—Vincristine—lymphatic system cancer	0.000512	0.000555	CcSEcCtD
Cevimeline—Nausea—Carmustine—lymphatic system cancer	0.000509	0.000551	CcSEcCtD
Cevimeline—Angiopathy—Methotrexate—lymphatic system cancer	0.000507	0.000549	CcSEcCtD
Cevimeline—Vomiting—Mitoxantrone—lymphatic system cancer	0.000506	0.000549	CcSEcCtD
Cevimeline—Rash—Mitoxantrone—lymphatic system cancer	0.000502	0.000544	CcSEcCtD
Cevimeline—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000502	0.000544	CcSEcCtD
Cevimeline—Chills—Methotrexate—lymphatic system cancer	0.000501	0.000543	CcSEcCtD
Cevimeline—Headache—Mitoxantrone—lymphatic system cancer	0.000499	0.000541	CcSEcCtD
Cevimeline—Alopecia—Methotrexate—lymphatic system cancer	0.000493	0.000535	CcSEcCtD
Cevimeline—Malnutrition—Methotrexate—lymphatic system cancer	0.000486	0.000527	CcSEcCtD
Cevimeline—Nausea—Vincristine—lymphatic system cancer	0.000486	0.000526	CcSEcCtD
Cevimeline—Dysgeusia—Methotrexate—lymphatic system cancer	0.000476	0.000516	CcSEcCtD
Cevimeline—Nausea—Mitoxantrone—lymphatic system cancer	0.000473	0.000513	CcSEcCtD
Cevimeline—Back pain—Methotrexate—lymphatic system cancer	0.00047	0.00051	CcSEcCtD
Cevimeline—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000451	0.000489	CcSEcCtD
Cevimeline—Anaemia—Methotrexate—lymphatic system cancer	0.000449	0.000487	CcSEcCtD
Cevimeline—Malaise—Methotrexate—lymphatic system cancer	0.000438	0.000475	CcSEcCtD
Cevimeline—Vertigo—Methotrexate—lymphatic system cancer	0.000437	0.000473	CcSEcCtD
Cevimeline—Leukopenia—Methotrexate—lymphatic system cancer	0.000435	0.000472	CcSEcCtD
Cevimeline—Cough—Methotrexate—lymphatic system cancer	0.000424	0.00046	CcSEcCtD
Cevimeline—Convulsion—Methotrexate—lymphatic system cancer	0.000421	0.000456	CcSEcCtD
Cevimeline—Myalgia—Methotrexate—lymphatic system cancer	0.000414	0.000448	CcSEcCtD
Cevimeline—Chest pain—Methotrexate—lymphatic system cancer	0.000414	0.000448	CcSEcCtD
Cevimeline—Arthralgia—Methotrexate—lymphatic system cancer	0.000414	0.000448	CcSEcCtD
Cevimeline—Discomfort—Methotrexate—lymphatic system cancer	0.000409	0.000443	CcSEcCtD
Cevimeline—Confusional state—Methotrexate—lymphatic system cancer	0.0004	0.000433	CcSEcCtD
Cevimeline—Infection—Methotrexate—lymphatic system cancer	0.000394	0.000427	CcSEcCtD
Cevimeline—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000389	0.000422	CcSEcCtD
Cevimeline—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000388	0.000421	CcSEcCtD
Cevimeline—Skin disorder—Methotrexate—lymphatic system cancer	0.000385	0.000418	CcSEcCtD
Cevimeline—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000383	0.000416	CcSEcCtD
Cevimeline—Anorexia—Methotrexate—lymphatic system cancer	0.000378	0.00041	CcSEcCtD
Cevimeline—Hypotension—Methotrexate—lymphatic system cancer	0.000371	0.000402	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000361	0.000392	CcSEcCtD
Cevimeline—Insomnia—Methotrexate—lymphatic system cancer	0.000359	0.000389	CcSEcCtD
Cevimeline—Paraesthesia—Methotrexate—lymphatic system cancer	0.000356	0.000386	CcSEcCtD
Cevimeline—Dyspnoea—Methotrexate—lymphatic system cancer	0.000354	0.000383	CcSEcCtD
Cevimeline—Somnolence—Methotrexate—lymphatic system cancer	0.000353	0.000382	CcSEcCtD
Cevimeline—Dyspepsia—Methotrexate—lymphatic system cancer	0.000349	0.000378	CcSEcCtD
Cevimeline—Decreased appetite—Methotrexate—lymphatic system cancer	0.000345	0.000374	CcSEcCtD
Cevimeline—Fatigue—Methotrexate—lymphatic system cancer	0.000342	0.000371	CcSEcCtD
Cevimeline—Pain—Methotrexate—lymphatic system cancer	0.000339	0.000368	CcSEcCtD
Cevimeline—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000327	0.000354	CcSEcCtD
Cevimeline—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000324	0.000352	CcSEcCtD
Cevimeline—Urticaria—Methotrexate—lymphatic system cancer	0.000315	0.000342	CcSEcCtD
Cevimeline—Abdominal pain—Methotrexate—lymphatic system cancer	0.000314	0.00034	CcSEcCtD
Cevimeline—Body temperature increased—Methotrexate—lymphatic system cancer	0.000314	0.00034	CcSEcCtD
Cevimeline—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000292	0.000317	CcSEcCtD
Cevimeline—Asthenia—Methotrexate—lymphatic system cancer	0.000285	0.000308	CcSEcCtD
Cevimeline—Pruritus—Methotrexate—lymphatic system cancer	0.000281	0.000304	CcSEcCtD
Cevimeline—Diarrhoea—Methotrexate—lymphatic system cancer	0.000271	0.000294	CcSEcCtD
Cevimeline—Dizziness—Methotrexate—lymphatic system cancer	0.000262	0.000284	CcSEcCtD
Cevimeline—Vomiting—Methotrexate—lymphatic system cancer	0.000252	0.000273	CcSEcCtD
Cevimeline—Rash—Methotrexate—lymphatic system cancer	0.00025	0.000271	CcSEcCtD
Cevimeline—Dermatitis—Methotrexate—lymphatic system cancer	0.00025	0.000271	CcSEcCtD
Cevimeline—Headache—Methotrexate—lymphatic system cancer	0.000248	0.000269	CcSEcCtD
Cevimeline—Nausea—Methotrexate—lymphatic system cancer	0.000236	0.000255	CcSEcCtD
